Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia

Phase 1

Completed

Conditions: Breast Cancer
Ovarian Cancer
Cachexia
Anorexia
Pancreatic Cancer
Colorectal Cancer
Prostate Cancer
Loss of Appetite
Non-small Cell Lung Cancer
Fatigue

Interventions: Drug: PF-06946860
Drug: Placebo for PF-06946860

First Posted Date: 2021-03-17

Last Posted Date: 2024-01-12

Lead Sponsor: Pfizer

Target Recruit Count: 18

Registration Number: NCT04803305

Locations: 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Medical Oncology Associates, PS (dba Summit Cancer Centers), Spokane Valley, Washington, United States
🇺🇸
MultiCare Regional Cancer Center - Tacoma, Tacoma, Washington, United States

and more 30 locations

PF-07284892 in Participants With Advanced Solid Tumors

Phase 1

Terminated

Conditions: Solid Tumor

Interventions: Drug: PF-07284892
Biological: cetuximab
Drug: binimetinib
Drug: lorlatinib
Drug: encorafenib

First Posted Date: 2021-03-16

Last Posted Date: 2024-10-22

Lead Sponsor: Pfizer

Target Recruit Count: 53

Registration Number: NCT04800822

Locations: 🇺🇸
Brigitte Harris Cancer Pavilion, Detroit, Michigan, United States
🇺🇸
Mayo Clinic in Arizona - Phoenix, Phoenix, Arizona, United States
🇺🇸
Mayo Clinic, Scottsdale, Arizona, United States

and more 13 locations

MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Participants With Multiple Myeloma

Phase 1

Conditions: Relapsed or Refractory Multiple Myeloma

Interventions: Drug: Elranatamab (PF-06863135)

First Posted Date: 2021-03-15

Last Posted Date: 2022-06-22

Lead Sponsor: Pfizer

Target Recruit Count: 4

Registration Number: NCT04798586

Locations: 🇯🇵
Japanese Red Cross Medical Center, Shibuya-ku, Tokyo, Japan
🇯🇵
Nagoya City University Hospital, Nagoya, Aichi, Japan

Efficacy and Safety of Ceftazidime-Avibactam (CAZ-AVI) in Chinese Participants With HAP (Including VAP)

Phase 4

Completed

Conditions: Hospital-Acquired Pneumonia

Interventions: Drug: Zavicefta, Ceftazidime-Avibactam

First Posted Date: 2021-03-01

Last Posted Date: 2023-08-31

Lead Sponsor: Pfizer

Target Recruit Count: 235

Registration Number: NCT04774094

Locations: 🇨🇳
Qingyuan People's Hospital, Qingyuan, Guangdong, China
🇨🇳
Shenzhen People's Hospital, Shenzhen, Guangdong, China
🇨🇳
Hainan General Hospital, Haikou, Hainan, China

and more 50 locations

Trial to Evaluate the Safety, Tolerability, and Immunogenicity of A Multivalent Group B Streptococcus Vaccine When Administered Concomitantly With Tdap in Healthy Nonpregnant Women

Phase 2

Completed

Conditions: Group B Streptococcus Infections

Interventions: Biological: Multivalent Group B streptococcus vaccine
Biological: Tetanus, diphtheria, and acellular pertussis vaccine
Biological: Placebo

First Posted Date: 2021-02-23

Last Posted Date: 2024-05-24

Lead Sponsor: Pfizer

Target Recruit Count: 306

Registration Number: NCT04766086

Locations: 🇺🇸
DM Clinical Research - Brookline, Houston, Texas, United States
🇺🇸
Accellacare - Raleigh, Raleigh, North Carolina, United States
🇺🇸
Accellacare - Wilmington, Wilmington, North Carolina, United States

and more 7 locations

First-line Palbociclib and Endocrine Therapy for Patients With HR+/HER2- Advanced Breast Cancer in the Real-world Setting.

Active, not recruiting

Conditions: Breast Neoplasms

Interventions: Drug: Palbociclib + endocrine therapy

First Posted Date: 2021-02-23

Last Posted Date: 2025-03-10

Lead Sponsor: Pfizer

Target Recruit Count: 1443

Registration Number: NCT04767594

Locations: 🇩🇪
imland gGmbH, Fockbek, Germany
🇩🇪
Gemeinschaftspraxis für internistische Hämatologie und Onkologie, Rheine, Germany
🇩🇪
Nadler GmbH, Rinteln, Germany

and more 191 locations

STUDY OF PF-07321332 IN HEALTHY PARTICIPANTS

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: PF-07321332 Dose 2
Drug: PF-07321332 Dose 3
Drug: PF-07321332 Dose 4
Drug: PF-07321332 Dose 5
Drug: PF-07321332 Dose 4 or Placebo (Fed)
Drug: PF-07321332 Dose 1

First Posted Date: 2021-02-16

Last Posted Date: 2024-10-15

Lead Sponsor: Pfizer

Target Recruit Count: 70

Registration Number: NCT04756531

Locations: 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium
🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States

Real World Data Collection Pediatric Neuroblastoma Treated With Lorlatinib

Terminated

Conditions: Neuroblastoma

Interventions: Drug: lorlatinib

First Posted Date: 2021-02-15

Last Posted Date: 2023-03-17

Lead Sponsor: Pfizer

Target Recruit Count: 15

Registration Number: NCT04753658

Locations: 🇳🇿
Starship Blood and Cancer Centre, Auckland, New Zealand
🇵🇹
Instituto Portugues de Oncologia de Lisboa, Lisboa, Portugal
🇸🇪
Queen Silvia Children's Hospital, Gothenburg, Sweden

and more 8 locations

Acute Respiratory Illness Surveillance (AcRIS) With Mobile Application in a Low-Interventional Decentralized Study.

Completed

Conditions: Healthy

Interventions: Diagnostic Test: SARS-CoV-2/Influenza/RSV RT-PCR

First Posted Date: 2021-02-10

Last Posted Date: 2024-02-23

Lead Sponsor: Pfizer

Target Recruit Count: 9151

Registration Number: NCT04748445

Locations: 🇺🇸
Ochsner Clinic Foundation, New Orleans, Louisiana, United States

Post Marketing Surveillance (PMS) Study of Cresemba in Korea.

Recruiting

Conditions: Aspergillosis
Mucormycosis

First Posted Date: 2021-02-09

Last Posted Date: 2025-06-17

Lead Sponsor: Pfizer

Target Recruit Count: 600

Registration Number: NCT04744454

Locations: 🇰🇷
Pfizer Korea, Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy